Form 4 for PCVX Vaxcyte, Inc.
Accepted 2024-10-22 00:00:00 ET · period of report 2024-10-18 · accession 0001649094-24-000082 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-10-22 | 2024-10-18 | PCVX | GUGGENHIME ANDREW | Pres AND CFO | M - OptEx | $5.35 | +42.0K | 132.4K | +46% | +$224.7K |
| DM | 2024-10-22 | 2024-10-18 | PCVX | GUGGENHIME ANDREW | Pres AND CFO | S - Sale+OE | $115.39 | -42.0K | 96.3K | -30% | -$4.85M |
| DM | 2024-10-22 | 2024-10-18 | PCVX | GUGGENHIME ANDREW | Pres AND CFO | M - OptEx | $0.00 | -42.0K | 278.8K | -13% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-10-18 | M | A | 12,000 | $5.35 | 118,383 | D | — | — | |
| 2 | Common | Common Stock | 2024-10-18 | M | A | 8,000 | $5.35 | 98,383 | D | — | — | |
| 3 | Common | Common Stock | 2024-10-18 | M | A | 8,000 | $5.35 | 106,383 | D | — | — | |
| 4 | Common | Common Stock | 2024-10-18 | S | D | 5,886 | $116.19 | 90,383 | D | — | — | (F3) The price reported is a weighted-average price. The shares were sold at prices ranging from $115.88 to $116.48. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| 5 | Common | Common Stock | 2024-10-18 | M | A | 14,000 | $5.35 | 132,383 | D | — | — | |
| 6 | Common | Common Stock | 2024-10-18 | S | D | 36,114 | $115.26 | 96,269 | D | — | — | (F2) The price reported is a weighted-average price. The shares were sold at prices ranging from $114.825 to $115.80. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| 7 | Derivative | Stock Option (right to buy) | 2024-10-18 | M | D | 8,000 | $0.00 | 312,827 | D | $5.35 · — to 2030-05-11 | 8,000 Common Stock | (F4) 1/4 of the shares subject to the option vested on May 1, 2021, and 1/48 of the shares vest monthly thereafter. |
| 8 | Derivative | Stock Option (right to buy) | 2024-10-18 | M | D | 8,000 | $0.00 | 304,827 | D | $5.35 · — to 2030-05-11 | 8,000 Common Stock | (F4) 1/4 of the shares subject to the option vested on May 1, 2021, and 1/48 of the shares vest monthly thereafter. |
| 9 | Derivative | Stock Option (right to buy) | 2024-10-18 | M | D | 12,000 | $0.00 | 292,827 | D | $5.35 · — to 2030-05-11 | 12,000 Common Stock | (F4) 1/4 of the shares subject to the option vested on May 1, 2021, and 1/48 of the shares vest monthly thereafter. |
| 10 | Derivative | Stock Option (right to buy) | 2024-10-18 | M | D | 14,000 | $0.00 | 278,827 | D | $5.35 · — to 2030-05-11 | 14,000 Common Stock | (F4) 1/4 of the shares subject to the option vested on May 1, 2021, and 1/48 of the shares vest monthly thereafter. |